- Home
- AMPL vs AUPH Comparison
AMPL vs AUPH Comparison
Compare AMPL & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPL
- AUPH
- Stock Information
- Founded
- AMPL 2012
- AUPH 1993
- Country
- AMPL United States
- AUPH Canada
- Employees
- AMPL N/A
- AUPH N/A
- Industry
- AMPL EDP Services
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- AMPL Technology
- AUPH Health Care
- Exchange
- AMPL Nasdaq
- AUPH Nasdaq
- Market Cap
- AMPL 1.7B
- AUPH 1.4B
- IPO Year
- AMPL 2021
- AUPH 1999
- Fundamental
- Price
- AMPL $11.53
- AUPH $11.37
- Analyst Decision
- AMPL Buy
- AUPH Strong Buy
- Analyst Count
- AMPL 10
- AUPH 4
- Target Price
- AMPL $13.70
- AUPH $12.25
- AVG Volume (30 Days)
- AMPL 1.5M
- AUPH 2.6M
- Earning Date
- AMPL 08-06-2025
- AUPH 07-31-2025
- Dividend Yield
- AMPL N/A
- AUPH N/A
- EPS Growth
- AMPL N/A
- AUPH N/A
- EPS
- AMPL N/A
- AUPH 0.42
- Revenue
- AMPL $316,571,000.00
- AUPH $260,111,000.00
- Revenue This Year
- AMPL $12.78
- AUPH $12.15
- Revenue Next Year
- AMPL $10.79
- AUPH $18.34
- P/E Ratio
- AMPL N/A
- AUPH $27.05
- Revenue Growth
- AMPL 9.93
- AUPH 25.59
- 52 Week Low
- AMPL $7.55
- AUPH $5.29
- 52 Week High
- AMPL $14.88
- AUPH $11.80
- Technical
- Relative Strength Index (RSI)
- AMPL 40.15
- AUPH 75.19
- Support Level
- AMPL $11.37
- AUPH $8.73
- Resistance Level
- AMPL $14.49
- AUPH $11.80
- Average True Range (ATR)
- AMPL 0.70
- AUPH 0.52
- MACD
- AMPL -0.10
- AUPH 0.24
- Stochastic Oscillator
- AMPL 6.77
- AUPH 86.77
About AMPL Amplitude Inc.
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue primarily through selling subscriptions to the platform. The company derives a majority of its revenue from the United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.